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Abstract
SIVmac239 infection of rhesus macaques (RMs) results in AIDS despite the generation of a strong antiviral cytotoxic T
lymphocyte (CTL) response, possibly due to the emergence of viral escape mutants that prevent recognition of infected
cells by CTLs. To determine the anatomic origin of these SIV mutants, we longitudinally assessed the presence of CTL escape
variants in two MamuA*01-restricted immunodominant epitopes (Tat-SL8 and Gag-CM9) in the plasma, PBMCs, lymph
nodes (LN), and rectal biopsies (RB) of fifteen SIVmac239-infected RMs. As expected, Gag-CM9 did not exhibit signs of escape
before day 84 post infection. In contrast, Tat-SL8 escape mutants were apparent in all tissues by day 14 post infection.
Interestingly LNs and plasma exhibited the highest level of escape at day 14 and day 28 post infection, respectively, with the
rate of escape in the RB remaining lower throughout the acute infection. The possibility that CTL escape occurs in LNs
before RBs is confirmed by the observation that the specific mutants found at high frequency in LNs at day 14 post infection
became dominant at day 28 post infection in plasma, PBMC, and RB. Finally, the frequency of escape mutants in plasma at
day 28 post infection correlated strongly with the level Tat-SL8-specific CD8 T cells in the LN and PBMC at day 14 post
infection. These results indicate that LNs represent the primary source of CTL escape mutants during the acute phase of
SIVmac239 infection, suggesting that LNs are the main anatomic sites of virus replication and/or the tissues in which CTL
pressure is most effective in selecting SIV escape variants.
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Introduction
Human immunodeficiency virus (HIV) infection of humans and
Simian Immunodeficiency Virus (SIV) infection of rhesus
macaques (Macaca mulatta, RM) results in a progressive and
irreversible decline of immune function characterized by depletion
of CD4 T cells, chronic immune activation, and high susceptibility
to opportunistic infections that is commonly referred to as AIDS.
While the host immune system mounts strong cellular and
humoral immune responses against HIV and SIV, these responses
ultimately fail to control virus replication in the overwhelming
majority of infected individuals. A key reason underlying this
immune failure is the extreme genetic variability of these primate
lentiviruses, which occurs as a result of a high mutation rate caused
by the relative infidelity of the HIV and SIV reverse transcriptases
[1]. This extreme genetic diversity combined with a large in vivo
effective population size [2] practically ensures that the virus will
always be able to evade or ‘‘escape’’ from recognition by the host
immune system. In clinical terms, these biological features of HIV
in the absence of ‘‘natural immunity’’ against the virus are key
indicators of the complexity and difficulty that the scientific
community faces when trying to design an effective AIDS vaccine.
In the absence of immunogens that are able to predictably elicit
the production of broadly reactive HIV- or SIV-specific
neutralizing antibodies [3,4], there has been significant interest
in immunogens that elicit strong antiviral CD8+ T cell-mediated
cytotoxic T lymphocyte (CTL) responses [5]. A large body of
evidence indicates that CD8+ T cells do play a significant role in
the control of HIV and SIV replication that involves both cytolytic
and non-cytolytic mechanisms. First, CD8+ T cells can inhibit
HIV and SIV replication in vitro [6,7]. Second, there is a temporal
association between post-peak decline of acute viremia and
emergence of CD8+ T cell responses [8,9]. Third, antibody-
mediated in vivo depletion of CD8+ lymphocytes is consistently
associated with increased virus replication in SIV-infected RMs
[10,11,12]. Fourth, there is a strong association between specific
major histocompatibility complex (MHC) alleles and ability to
control virus replication during HIV and SIV infection [13]. In
this context, the fact that CTL escape mutants consistently arise
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demonstrate the presence of selective CD8+ T cell-mediated
immune pressure on the virus population. On the other hand, the
fact that escape mutants are consistently observed is also an
indicator of the overall inability of these cells to fully suppress virus
replication.
SIVmac239 infection of RMs bearing the MamuA*01 MHC class
I allele elicits CD8+ T cell responses against two very well
characterized immunodominant epitopes: Tat-SL8 [14] and Gag-
CM9 [15]. While SL8- and CM9-specific CD8+ T cell responses
are both generated during the acute phase of infection [14,16], the
emergence of CTL escape mutants occurs much more rapidly in
the Tat-SL8 epitope than it does in Gag-CM9 [14,17,18],
presumably due to strong functional constraints imposed on the
gag gene and the need for extra-epitopic, secondary compensatory
mutations to allow effective virus replication [19,20,21]. Of note,
in these studies the kinetics of the generation and fixation of CTL
escape mutations occurring in the SL8 and CM9 regions of SIV
was analyzed only in plasma virus, which is thought to provide an
overall representation of the virus that are replicating within the
host. However, to the best of our knowledge, a comprehensive and
comparative longitudinal analysis of CTL escape mutants in the
mucosal and lymphoid tissues of SIV-infected RMs has not been
yet been conducted. Determining if CTL escape mutants emerge
more rapidly in lymphoid or, alternatively, mucosal tissues would
provide important information with respect to the predominant
sites of CD8+ T cell-mediated immunological pressure in vivo.
In this study, we characterized the appearance, dynamics, and
dissemination of CD8+ T cell escape mutants in lymphoid vs
mucosal tissues during SIVmac239 infection of RMs. To this end,
we conducted an extensive longitudinal assessment of viral
sequences derived from plasma viral RNA as well as cell-associated
viral DNA in peripheral blood mononuclear cells (PBMC), lymph
node biopsies (LN), and biopsies of the rectal mucosa (RB) of 15
SIV-infected RMs. These animals were included in a previously
published study designed to investigate the immunogenicity and
protection from SIVmac239 challenge conferred by two MVA-base
candidate AIDS vaccines expressing SIVmac gag and tat [22]. As
expected, we observed that CTL escape mutants occurred early in
the Tat-SL8 epitope and much later in the Gag-CM9 epitope.
Importantly, we found that in all RMs, Tat-SL8 escape mutants
appeared earlier and in higher frequency in LNs then in RBs, with
variants found at high frequency in LNs at day 14 post infection
becoming dominant in the RBs at day 28 post infection. These
results indicate that LNs represent the primary source of CTL
escape mutants during the acute phase of SIVmac239 infection,
suggesting that LNs are the main anatomic sites of virus replication
and/or the tissues in which CTL pressure is most effective in
selecting SIV escape variants.
Results
Experimental design: SIVmac239 infection of 10
MVA-SIVgag/tat-vaccinated and 5 unvaccinated
rhesus macaques
A group of fifteen MamuA*01-positive rhesus macaques (Macaca
mulatta; RM) were infected intravenously with 10,000 TCID50 of
SIVmac239 as part of a previous study designed to assess the
immunogenicity and potential protection from challenge conferred
by MVA-based candidate AIDS vaccines [22]. In this study, ten
RMs were immunized three times with either MVA ‘‘wild-type’’ (5
animals) or a genetically engineered MVA in which the gene for
the Uracil DNA Glycosidase (UDG) was deleted, i.e. DUDG (5
animals), with both vectors expressing the Gag and Tat proteins of
SIVmac239. Five additional unvaccinated RMs were used as
controls. In all animals, SIV-specific CD8+ T cell responses were
measured at various time points post-immunization and post-
challenge in multiple tissues, including PBMC, RB, and LN by
tetramer staining for the Gag-CM9 and Tat-SL8 epitopes of
SIVmac239. The main results of this study are summarized in Table
S1. Briefly, administration of MVA-SIV immunogens resulted in a
partial (,1 log) and transient (60–120 days) decline in plasma viral
load that did not translate into protection from CD4+ T cell
depletion and disease progression. Of note, in four RMs the level
of virus replication decreased to near undetectable levels during
the chronic phase of infection, suggesting that these ‘‘controller’’
animals were able to mount antiviral immune responses that could
successfully suppress virus replication in vivo. The large amount of
virologic and immunologic data collected in this study combined
with an extensive archive of tissue samples presented an ideal
opportunity to explore in detail the relationship between SIV-
specific CD8+ T cell responses in various tissues, and the
appearance and dissemination of CTL escape mutants in a
relatively large cohort of SIVmac239-infected RMs. Due to
relatively modest protective effect of the used immunization
regimen [22], we chose to conduct our analysis in the entire group
of 15 SIV-infected animals without dividing them into vaccinated
and controls.
To characterize the emergence of CTL escape mutants in our
cohort of SIVmac239-infected RMs, we amplified a 435 nucleotide
region surrounding the Gag-CM9 epitope and a 390 nucleotide
region surrounding the Tat-SL8 epitope from reverse transcribed
plasma viral RNA and genomic DNA derived from PBMCs, RB,
and LNs collected at multiple time points post infection. These
amplicons were then sequenced from one end using Roche’s 454
pyrosequencing technology. After eliminating all sequence reads
that did not meet the minimum set of quality criteria (see Materials
and Methods), source animals for each read were identified via
pre-determined barcodes, and the reads were aligned with the
corresponding wildtype SIVmac239 sequence. High frequency
insertions and deletions (indels) that resembled well-characterized
artifacts of the 454 pyrosequencing procedure were repaired with
reference to the wildtype SIVmac239 sequence. All resulting
sequences that contained no indels and were at least 243
Author Summary
Strong antiviral CD8+ T lymphocytes limit SIV replication
by recognizing short pathogen-derived peptide epitopes.
The cytotoxic CD8+ T cell responses specific for this highly
mutable virus can select for viruses bearing mutations that
prevent CD8+ T cell recognition of cells infected with these
escape mutants. To determine the anatomic origin of
these escape mutants, we tracked a particular escape
mutant in multiple tissues (plasma virus, lymph nodes,
rectal mucosa, and peripheral blood immune cells) during
the early, acute phase of SIVmac239 infection of rhesus
macaques. We found that escape mutants first reach high
frequency in lymph nodes 2 weeks after infection, and the
particular mutants generated in lymph nodes disseminate
to other tissues by week 4. Furthermore, we found that
epitope-specific CD8+ T lymphocyte responses in the
lymph nodes and peripheral blood, but not the gut
mucosa, are significantly correlated with the frequency of
escape mutants in the plasma virus at week 4. This
suggests that lymph nodes, and not the gut, are the
primary site of anti-SIV CD8+ T cell responses and/or SIV
replication during the acute phase of infection.
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SL8 were included in all subsequent analyses. To ensure that the
sequence selection process did not bias our results, all analyses
were performed on the full set of reads that had been repaired
indiscriminately using the SIVmac239 wildtype sequence. No bias
was found in our results (data not shown).
Escape in Gag-CM9 occurred in only two RMs during the
chronic phase of infection via mutation of a single
anchor residue
HIV and SIV gag genes are highly conserved and thus escape
mutations in CD8+ T cell epitopes in this region are typically
associated with either highly unfit viruses or the appearance of
compensatory mutations outside of the epitope itself [20]. In order
to characterize the rate and mechanisms of escape in the highly
conserved Mamu-A*01-restricted Gag-CM9 epitope in our SIV-
mac239 infected RMs, we amplified and sequenced this epitope from
plasmavirusand cell-associatedviral DNAinPBMCs, LN, andRB.
Escape in Gag-CM9 occurred via mutations at the second position
(threonine) in the epitope (Figure 1A). The substituted amino acids
observed included serine, isoleucine, and cysteine. Interestingly, the
threonine to cysteine amino acid substitution is achieved via a
nucleotide substitution at the first and second positions of the
threonine codon and was observed in the RB butnot other tissues of
a single animal, RDo8 (data not shown). There was no evidence of a
significant increase in the frequency of the intermediate codons,
thus suggesting that viruses bearing the resultant amino acid
substitutions are at a severe selective disadvantage. However, it is
also possible that the frequency of sampling during the chronic
phaseofSIVmac239infectionwasnotsufficienttodetectthepresence
of relatively transient intermediate amino acid substitutions. As
expected based on previous studies [17,18,20], escape in Gag-CM9
was observed in only two RMs (RDo8 and RWi8) and not until day
84 post infection, when escape mutants appeared in plasma virus
and, although at lower frequencies, in PBMC-derived cell-
associated virus (Figure 1B). In these two animals viruses isolated
from RBs at day 168 post infection were almost entirely comprised
of Gag-CM9 escape mutants (Figure 1B).
Escape in Tat-SL8 occurred rapidly in plasma virus via
multiple intra-epitopic amino acid substitutions
Previousstudiesofthekinetics ofemergenceofCTLescapeinthe
Mamu-A*01-restricted Tat-SL8 immunodominant epitope have
shown that in plasma virus, Tat-SL8 escape occurs during the early
Figure 1. The gag-CM9 MamuA*01-restricted SIVmac239 CD8 T cell epitope escaped via a mutation of a single anchor residue that
was observed late during the chronic phase of infection. (A) Four example amino acid alignments of the gag-CM9 epitope (indicated in grey)
showing the changes in plasma viral populations between a baseline time point (day 7 post infection) and a time point in which escape is evident
(day 84 post infection) in a two animals (RDo8 and RWi8). The proportion of reads bearing the sequence shown is indicated to the right of each line in
the alignment. (B) The level escape at gag-CM9, expressed as the frequency of reads bearing the wildtype epitope in plasma virus, PBMC, LN and RB.
doi:10.1371/journal.ppat.1002048.g001
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[14,23,24]. For this reason, we focused our analysis of the
emergence of Tat-SL8 escape mutants in our group of SIVmac239-
infected RMs during the acute phase of infection. As described for
the Gag-CM9 epitope, we PCR amplified the viral genomic region
surrounding the Tat-SL8 epitope from reverse transcribed plasma
viral RNA and sequenced it by 454 pyrosequencing.
As expected based on previous studies [14,23,24], the emergence
of Tat-SL8 escape mutants consistently occurred at high frequency
during acute SIV infection. In particular, we observed that CTL
escape in Tat-SL8 occurred through one or more of several amino
acid substitutions: serine to proline or phenylalanine at position 1,
threonine to isoleucine at position 2, serine to leucine at position 5,
and alanine to aspartic acid at position 6 (Figure 2A). These amino
acid substitutions occur through single nucleotide mutations and
have all been characterized as escape mutations in previous studies
[14,23,24]. As shown in Figure 2B, Tat-SL8 escape mutants began
to emerge by day 14 post infection in most RMs, with especially
high levels of escape mutants evident in 4 animals (RDo8, ROu8,
RWi8, RWu8). By day 28 post infection, the majority of plasma
virus in all SIV-infected RMs was comprised of Tat-SL8 escape
mutants, with the median frequency of the wildtype Tat-SL8
epitope at 0.08 (range, 0.008–0.261; Figure 2B). The frequency of
the viruses bearing the wildtype Tat-SL8 epitope continued to
decrease through day 84 post infection (mean, 0.01; range, 0.004–
0.027). Overall, these data confirm the early emergence of
numerous Tat-SL8 escape mutants, a finding that reflects both
the selective pressure exerted by Tat-SL8-specific CD8+ T cell
responses and the relative genetic flexibility of Tat in maintaining its
function despite the presence of these mutations [19].
Lymph nodes andrectalbiopsies aretheprimarysourceof
Tat-SL8 escape mutants during acute SIVmac239 infection
To investigate the kinetics of appearance and dissemination of
escape mutants in SIVmac239 infection in different anatomic
compartments, we next compared both the frequency and the
character of Tat-SL8 CTL escape mutants in viral sequences
derived from plasma virus and cell-associated viral DNA from
peripheral blood mononuclear cells (PBMCs), lymph nodes (LNs)
and intestinal mucosa that was sampled by rectal biopsies (RB).
This analysis was performed on samples obtained at day 14 and
day 28 post infection. While Tat-SL8 escape mutants were evident
in all four examined tissues at day 14 post infection, LNs exhibited
a significantly higher frequency of escape mutants than either
plasma or RB (Figure 3A; p=0.0022, Kruskal-Wallis with Dunn’s
multiple comparisons). Interestingly, the discrepancy in the level of
escape between LNs and plasma virus may be seen as reflecting
the fact that circulating virus at the peak of acute SIV infection
originates primarily from other tissues. By day 28 post infection,
plasma virus exhibited a greater level of Tat-SL8 escape than cell-
associated virus sampled from either PBMCs or RBs (Figure 3B;
p=0.0001, Kruskal-Wallis with Dunn’s test for multiple compar-
isons), but not from LNs. This finding suggests that plasma virus
during the phase of post-peak decline in viremia is likely to
originate primarily in lymphoid tissues.
Escape in Tat-SL8 can occur through multiple amino acid
substitutions [14,23,24]. In order to further delineate the sources
of actively replicating viruses that contain Tat-SL8 escape mutants
during acute SIVmac239 infection of RMs, we next characterized
the frequency distribution of distinct intra-epitopic Tat-SL8 escape
mutations. We found that, in the majority of RMs, Tat-SL8 escape
mutants sampled from LNs at day 14 post infection were
dominated by a serine to proline amino acid substitution at the
first position of the epitope, although amino acid substitutions at
other positions were observed at much lower frequency (Figure
S1A). This pattern of amino acid substitution observed in LNs
appeared to be different from what we observed in the Tat-SL8
genotypes sampled from the other three examined tissues, in which
there was no clearly dominant amino acid substitution (Figure
S1A). In particular, the distribution of Tat-SL8 escape mutants in
Figure 2. The tat-SL8 MamuA*01-restricted SIVmac239 CD8 T cell epitope escaped rapidly in the plasma virus via multiple amino
acid substitutions during the acute phase of infection. (A) Two example amino acid alignments of the tat-SL8 epitope (indicated in grey)
showing the changes in plasma viral populations between a baseline time point (day 7) and a time point in which escape is evident (day 28) in a
single animal (RNr8). The proportion of reads bearing the sequence shown is indicated to the right of each line in the alignment. (B) The level escape
at tat-SL8 in plasma virus expressed as the frequency of reads bearing the wildtype epitope during the first 84 days post infection.
doi:10.1371/journal.ppat.1002048.g002
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viral DNA from PBMCs, with small, equivalent frequencies of
mutation at the first, second, fifth and eighth positions, than that of
either RBs or LNs. Of note, by day 28 post infection, the
distribution of Tat-SL8 escape mutants had become more similar
across all tissues (Figure S1B). However, while we observed an
increase in the relative abundance of mutations at positions 2
through 8 in LNs, the serine to proline mutation at the first amino
acid position of Tat-SL8 continued to be dominant (Figure S1B).
In fact, this particular escape mutation became the most frequently
sampled mutation in all tissues at day 28 post infection (Figure 3C;
2-way ANOVA with Bonferroni multiple comparison test,
p,0.001), and continued to dominate viral populations through
the latest time points sampled from all tissues (data not shown).
The persistent high frequency of this escape mutation at the first
position of Tat-SL8 suggests that anti-SIV immune responses
during the acute infection in lymphoid tissues rather than at
mucosal sites have a more lasting effect on the evolution of the SIV
viral population.
Interestingly, three of the four RMs exhibiting relatively large
numbers of escape mutants at day 14 post infection had been
vaccinated with the MVA-SIV vector (Figure S1A), thus
suggesting an early CTL-driven selection of these viral variants.
Indeed, vaccinated RMs showed a non-significant trend towards
increased frequencies of Tat-SL8 escape mutants at day 14 post
infection compared to unvaccinated controls (p.0.05, Kruskal-
Wallis with Dunn’s test for multiple comparisons). However,
vaccination did not preferentially increase the level of Tat-SL8
specific CD8+ T cells in LNs compared to PBMCs and RBs at
days 228, 0, and 7 post infection (Figure S2). Taken together these
observations argue against the possibility that the expansion of
Tat-SL8 escape mutants in LNs was caused primarily by vaccine-
induced prior expansion or redistribution of Tat-SL8-specific CD8
T cells to lymphoid tissues.
The frequency of Tat-SL8 escape mutants at day 28 post
infection is correlated with the magnitude of SIV-specific
immune responses at day 14 post infection
The large amount of virological and immunological data
collected during the course of SIVmac239 infection in the RMs
included in this study allowed us to probe whether specific
immune responses or virological outcomes (see Table S1) were
Figure 3. Escape in tat-SL8 was most evident in LN at day 14 post infection and variants generated there had spread to other
tissues by day 28 post infection. (A–B) The level of tat-SL8 escape mutants expressed as the frequency of the wildtype sequence in plasma virus
(PL), peripheral blood mononuclear cells (PBMC), lymph nodes (LN), and rectal biopsies (RB) at day 14 (A) and day 28 post infection (B). Significant
differences were determined with the Kruskal-Wallis test with Dunn’s Multiple Comparisons **: p,0.01, ***: p,0.001. (C) The average frequency of
mutations per amino acid position in tat-SL8 across all animals is shown. 2-way ANOVA using the Bonferroni Correction for multiple comparisons;
***: p,0.001. In each case the frequency of mutants at the first position (‘‘S’’) at day 28 post infection is compared individually to that at the other 7
amino acid positions in the epitope. This comparison was only significant in LNs at day 14 post infection.
doi:10.1371/journal.ppat.1002048.g003
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14 and 28 post infection. We did not find any significant
correlations between the levels of escape mutants in any tissue at
day 14 post infection and the levels of SIV-specific CD8+ T cell-
mediated immune responses as measured by tetramer staining at
the same time point. Furthermore, none of the virological
parameters measured at days 14 and 28 post infection correlated
with the level of escape mutants present in any tissue at the same
time points. However, we observed a clear correlation between
immune responses at day 14 post infection and the level of Tat-
SL8 escape present in several tissues at day 28 post infection
(Figure 4). First, the frequency of viruses bearing the wildtype Tat-
SL8 epitope among plasma viruses at day 28 post infection was
significantly inversely correlated with the abundance of anti-Tat-
SL8 CD8+ T cells at day 14 post infection in LNs (Figure 4A;
Spearman’s correlation, r=0.6592, p=0.0075) and PBMCs
(Figure 4B; Spearman’s correlation, r=0.5836, p=0.0224), but
not RBs (Figure 4C; Spearman’s correlation, r=0.4850,
p=0.787), suggesting that LNs are the major anatomic sites
where the anti-SIV CD8 T cell response is exerting immunological
pressure at the peak of acute SIVmac239 infection. Second, the
frequency of wildtype Tat-SL8 epitope in RBs and PBMCs at day
28 post infection was strongly correlated with levels of Tat-SL8
CD8+ T cells in RBs at day 14 post infection (Figure 4D–E;
Spearman’s correlation, RB: r=0.7992, p=0.001; PBMC:
r=0.6485, p=0.0121), perhaps suggesting a local effect of
mucosal SIV-specific CTL responses in determining the emer-
gence of escape mutants. Third, the levels of Gag-CM9-specific
CD8+ T cell responses in RBs at day 14 post infection also
correlated strongly with the frequency of tat-SL8 escape mutants
in RBs (Figure 4F; Spearman’s correlation, r=0.6731,
p=0.0164), but not PBMCs (data not shown) at day 28 post
infection. Interestingly, despite the significant correlations between
the frequency of Tat-SL8 escape and the magnitude of anti-SIV
CD8 T cell responses in various tissues, the decline in CD4+ T
cells in RB and PBMC did not correlate with the frequency of
escape at 14 and 28 days post infection in any tissue (data not
shown). Taken together these findings indicate that SIV-specific
CTL responses at the peak of acute infection have a strong impact
on the resultant viral population, with the pattern of observed
circulating virus variants at day 28 post infection being shaped
predominantly by LN-based immune responses.
RMs that control virus replication harbor higher levels of
proviruses bearing the wildtype Tat-SL8 in PBMC than
non-controller animals
Four SIV-infected RMs included in the current study (three
vaccinated and one control) were able to spontaneously control
virus replication to near undetectable levels shortly after the
resolution of acute viremia (Table S1). These RMs exhibited a ,1
log lower peak of acute viremia, yet similar levels of SIV-specific
CD8+ T cell responses as the normal non-controller animals. To
understand the contribution of CD8+ T cell escape to the control
of SIV replication, we compared the prevalence of Tat-SL8 escape
mutants and the diversity of virus sequences between the controller
and non-controller groups of SIV-infected RMs. Control of
SIVmac239 replication in RMs was associated with increased levels
of viruses bearing the wildtype Tat-SL8 epitope among infected
cells in PBMCs (Figure 5A; 2-way ANOVA using the Bonferroni
Correction for multiple comparisons) while viruses circulating in
the plasma were primarily escape mutants in both groups
(Figure 5B). Similarly, viruses sampled from RBs in controllers
at day 168 post infection were also composed primarily of viruses
bearing the wildtype Tat-SL8 epitope (data not shown). It should
Figure 4. Anti-SIV immune responses in lymphoid tissues and rectal mucosa at day 14 post infection were significantly correlated
with the level of tat-SL8 escape at day 28 post infection in the plasma virus and rectal mucosa, respectively. (A–B) The frequency of the
wildtype tat-SL8 at day 28 post infection in plasma virus plotted against the percentage of tat-SL8-tetramer-positive CD8 T cells at day 14 post
infection in lymph nodes (A) and PBMCs (B). (C–F) The frequency of wildtype tat-SL8 at day 28 post infection in RB (C,E) and PBMC (D,F) plotted
against the percentage of tat-SL8-tetramer-positive (C–D) and gag-CM9-tetramer-positive (E–F) CD8 T cells in RB at day 14 post infection. Spearman’s
correlation was used to determine the degree of correlation in all comparisons.
doi:10.1371/journal.ppat.1002048.g004
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samples of only two of the four controller. Finally, Tat-SL8 and
the surrounding region more closely resembled wildtype SIVmac239
in viruses sampled at late time points from PBMC, but not plasma,
of controllers than non-controllers (Figure 5C–D; 2-way ANOVA
using the Bonferroni Correction for multiple comparisons). In the
setting of low virus replication, as in our controller SIV-infected
RMs, virus isolated from cellular samples may include a large
representation of archival sequences as compared to plasma. As
such, it is possible that the large frequency of wildtype viruses in
the controllers is a consequence, rather than a cause, of the low
virus replication.
Discussion
Despite the presence of a strong antiviral immune response,
HIV infection of humans and SIV infection of RMs usually results
in a chronic and progressive immunodeficiency. The inability of
anti-SIV immune responses to effectively control virus replication
is at least partially due to the singular ability of this primate
lentivirus to evade immune responses via a high rate of genetic
mutation [13]. The epidemic circulation of extremely diverse viral
subtypes and the immune-mediated selection of viral escape
variants are two of the main problems that must be overcome by
a successful candidate HIV vaccine [25]. In the setting of
experimental SIV infection of non-human primates, the com-
parison of virus sequences obtained in different tissues might be
used to determine the anatomic origin of these escape variants.
We postulate that this analysis will help us define the anatomic
compartments where immune responses have their greatest
impact on virus replication and fitness. In addition, as plasma
virus includes all viral variants produced in the body at any given
time, a comparative kinetic analysis of the emergence of viral
escape mutants in plasma vs. tissues could provide an indirect but
robust measure of the extent of virus replication in the examined
tissues. Identifying these anatomic sites of high viral replication
and dominant immune pressure during the acute phase of HIV/
SIV infection might help the design of a vaccine that can elicit
adaptive immune responses capable of durable control of HIV
replication.
In order to define these sites of virus replication and immune
pressure during acute SIVmac239 infection of RMs, we investi-
gated the kinetics and characteristics of escape in two well
characterized Mamu-A*01-restricted CTL epitopes (Gag-CM9
and Tat-SL8). We sequenced the SIV genomic regions
containing these epitopes in longitudinal archival samples of
Figure 5. Control of SIVmac239 replication was associated with significantly higher levels of cell-associated viral DNA bearing the
wildtype tat-SL8 sequence in PBMC but not in plasma viral RNA. (A–B) The average frequency of wildtype tat-SL8 in controllers and non-
controllers was determined in PBMC (A) and plasma virus (B). (C–D) The average nucleotide sequence divergence from the wildtype sequence in the
220 nucleotide region surrounding tat-SL8 is shown in PBMC (C) and plasma virus (D). 2-way ANOVA using the Bonferroni Correction for multiple
comparisons; *: p,0.05, **: p,0.01, ***: p,0.001.
doi:10.1371/journal.ppat.1002048.g005
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and RBs collected from a cohort of vaccinated and challenged
RMs [22]. Ten of the rhesus macaques in this study had been
vaccinated with MVA-derived vectors expressing the Gag-CM9
and Tat-SL8 epitopes, while five of the challenged RMs were
unvaccinated. While our data do not rule out the possibility that
other tissues (i.e., spleen, liver, etc) are significant contributors to
plasma viremia and/or immune pressure, the unique aspect of
this study is the direct comparison between plasma, LNs, PBMCs,
and RBs.
As expected, Gag-CM9 escape mutants were observed in only
two animals and after day 84 post infection, while the Tat-SL8
epitope acquired escape mutations very quickly during the acute
phase infection. Interestingly, the comparative analysis of Tat-SL8
escape mutants revealed, at day 14 post infection, a higher
frequency in LN as compared to other tissues. By day 28 post
infection, Tat-SL8 escape mutants had become dominant in
plasma virus, and were found at higher frequency in LNs as
compared to RBs. Of note, at day 14 post infection virus escape
mutants in LNs, but not other tissues, were overwhelmingly
comprised of mutations at the first amino acid of the epitope.
These mutants became dominant in all tissues by day 28 post
infection. Taken together, these results suggest that, during acute
SIVmac239 infection, lymph nodes are the main sites of virus
replication and/or cellular immune pressure.
The large amount of virological and immunological data
collected during the original vaccination and challenge study of
these SIV-infected RMs [22] allowed us to more explicitly test
hypotheses regarding the immunological processes and anatomic
compartments that ultimately produced these viral escape
mutants. By correlating immune responses and changes in viral
dynamics with the level of escape in the examined tissues, we can
determine not only the origin of escape mutants, but the immune
responses responsible for their generation. We found that the level
of Tat-SL8-specific immune responses in LNs, and to a lesser
extent PBMCs, at day 14 post infection correlated strongly with
the level of escape in plasma virus at day 28 post infection. On the
other hand, SIV-specific immune responses in RBs at day 14 post
infection did not correlate with the level of Tat-SL8 escape at day
28 in plasma virus. Therefore, LNs rather than mucosal tissues
appear to be the tissue in which the strongest immune pressure
shapes the genetic composition of the currently replicating virus
population during the phase of post-peak decline of viremia in
SIV-infected RMs.
In addition, we observed that, in controller SIV-infected RMs
(but not in non-controller RMs), a large proportion of PBMC-
derived proviruses during the chronic phase of infection
exhibited the wildtype Tat-SL8 rather than the escaped epitope.
This high frequency of wildtype virus in controller RMs may be
the result of the early establishment of a wildtype latent viral
reservoir, which, due to their low level of replication, appears
over-represented as compared with the non-controller animals.
Since the actively replicating virus (i.e., in plasma) contains very
few, if any, viruses bearing the wildtype Tat-SL8, these wildtype
PBMC-associated viruses are likely to be either latent or non-
replication competent.
The observation that immune responses in LNs are more
important for shaping post acute viral populations is somewhat
surprising as the gut-associated lymphoid tissue has been
implicated as the major source of virus replication during the
acute phase of SIV infection [26,27,28,29,30]. One possibility is
that, during the post-peak decline of viremia, the gut mucosa is a
relatively isolated site of SIV replication, with slower migration of
virions from the intestinal interstitial fluids into the systemic
circulation as compared to LNs. Indeed, there is evidence for
compartmentalization of HIV within the gut [31] suggesting that
virus does not move freely within this tissue. An alternative
possibility is that the level of immunological pressure, rather than
the absolute level of virus production, is responsible for the
directional appearance of CTL escape mutants from LNs to
mucosal tissues. This concept fits with the fact that during acute
SIV infection LNs are the site of antigen-specific CD8+ T cell
expansion from the naı ¨ve pool, with virus-infected cells encoun-
tering anti-SIV CD8+ T cells more frequently than in the
intestinal lamina propria. These data are also consistent with the
possibility that the gut is not the main source of virus replication
during acute SIV infection, as recently suggested in a modeling
study [32]. However, we could not rule out the possibility that the
mutations in Tat simply provide a selective advantage to viruses in
lymphoid tissue (or less of a disadvantage relative to viruses
replicating in gut mucosal tissues) independently of their effects on
immune recognition.
While our study agrees with the numerous published articles
that have characterized immune escape in SIVmac239 infected
RMs [14,15,17,23,33,34,35,36,37], in almost all of these studies,
CTL escape mutants were assessed only in plasma virus. Our
study is unique in that we examined virus in multiple
longitudinal tissue samples (PBMC, LNs, and RBs) in addition
to the plasma virus. We are in fact aware of only a single study
that examined SIVmac239 escape mutants in multiple tissues
[38], but this study focused only on Gag-CM9 escape measured
at a single time point during the chronic infection. It will be
important to determine whether the pattern of escape seen in
Tat-SL8 during the acute infection is a general phenomenon for
CTL epitopes that escape during the acute phase of infection
with little or no measurable effects on viral fitness. In addition it
will be informative to characterize the anatomic distribution of
CTL epitopes that escape during the chronic phase of SIV
infection (e.g. Gag-CM9) by designing new studies in which
tissue samples are collected accordingly. Furthermore, future
studies should address whether the cell-associated viral sequenc-
es sampled from relatively small biopsies of the rectal mucosa
are representative of the gut as a whole. While this caveat
applies to most studies of gut-associated lymphoid tissue in the
setting of SIV infection, it is possible that our current results are
biased by the limited number of samples available for virus
sequencing.
It is unclear whether and to what extent the particular pattern
of CTL escape observed in our cohort of SIV-infected RMs
represents a generalized phenomenon or, alternatively, is the
result of this specific experimental design (i.e., intravenous high
titer infection), which does not mimic the typical route and
circumstances surrounding HIV infection of humans. Further-
more, the route of infection may influence the anatomic pattern
of emergence of CTL escape mutants. For example, a rectal
challenge model might result in the early seeding of local draining
lymph nodes with virus whereas an intra-venous challenge could
possibly disseminate virus more efficiently to systemic lymphoid
tissues throughout the body. Future studies in which RMs are
infected with low dose intra-rectal or intra-vaginal challenge will
help determine how the route and dose of infection influences the
early kinetics of CTL escape. Additionally, while the MVA
vaccination regime in this study did not protect from SIV disease
progression, it would be interesting to determine whether more
successful vaccines (i.e., rhesus CMV [39] and AdHu26 [40])
alters the dissemination of viral escape variants and/or the
pattern of immune responses during the acute phase of SIV
infections.
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Ethics statement
These studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, and
were approved by the Emory University (AWA# A3180-01) and
University of Pennsylvania (AWA# A3079-01) Institutional
Animal Care and Use Committees. All animals were anesthetized
prior to the performance of any procedure, and proper steps were
taken to ensure the welfare and to minimize the suffering of all
animals in these studies.
Immunization and SIVmac239 infection of RMs
The design of the SIV immunization and challenge study in
RMs that has been used as a source of samples for the current
manuscript are published elsewhere [22]. Briefly, ten RMs were
divided in two groups of five animal and immunized three times
with either one of two MVA vaccine vectors (i.e., wildtype and a
genetically modified MVA in which the udg gene was deleted)
expressing the SIVmac239 gag and tat genes. One year after the
initial immunization, all ten animals as well as five unvaccinated
control RMs were inoculated i.v. with 10,000 TCID50 of
SIVmac239. Throughout the immunization and challenge phase
plasma, peripheral blood mononuclear cells (PBMC), lymph node
biopsies (LN) and biopsies of the rectal mucosa (RB) were collected
for virological and immunological analysis (see Table S1). The
MHC-class I genotypes of all fifteen RMs were determined
courtesy of Dr. David Watkins. Of note, exclusion of the only
MamuB*08+ and MamuB*17+ animal did not change the result
of our analyses.
Tetramer staining
PBMC were collected by gradient centrifugation. LN and RB
were processed fresh as previously described. The levels of Tat-
and Gag- specific CD8 T cells were assessed via staining with
Streptavidin-APC conjugated class I MHC tetramers folded with
the Tat28-35-SL8 (STPESANL) or Gag181-189-CM9 (CTPY-
DINQM) peptide epitopes according to standard procedures.
Tissue processing and viral sequence amplification
Genomic DNA was purified from thawed PBMC samples using
the QIAamp DNA blood mini kit (Qiagen; Valencia, CA), and
from whole Streck-fixed, paraffin embedded RBs or from 50 mM
slices of formalin-fixed, paraffin embedded LNs using the QIAamp
DNA FFPE tissue kit (Qiagen; Valencia, CA). Viral RNA was
extracted from plasma samples using the Qiagen’s Viral RNA
mini kit (Valencia, CA). Viral cDNA was reverse transcribed using
Invitrogen’s SuperScript III and primers specific for sequences
upstream of the tat (Tat-RT3: 59-TGGGGATAATTTTACA-
CAAGGC-39)o rgag (Gag-RT2: 59-AGCTTGCAATCTGGGT-
TAGC-39) amplicons.
Viral sequences were amplified from purified genomic DNA or
viral cDNA in a nested two step PCR. The thermal cycler
program for the first round was: 94uC for 2:00; cycle 94uC for
0:30, 55uC for 0:30, and 68uC for 1:00, 35 times; and then a final
68uC for 7:00 before cooling to 4uC. After the tenth cycle, the
extension step (68uC) is extended by 5 seconds every cycle to
account for the degrading polymerase. The thermal cycler
program for the second round was: 94uC for 2:00; cycle 94uC
for 0:30, 53uC for 0:30, and 68uC for 1:00, 35 times; and then a
final 68uC for 7:00 before cooling to 4uC. The first round primers
for tat were Tat-F1 (59-GATGAATGGGTAGTGGAGGTTC-
TGG-39) and Tat-R2 (59-CCCAAGTATCCCTATTCTTGGT-
TGCAC-39), and the first round primers for gag were Gag-F1 (59-
GAGACACCTAGTGGTGGAAACAGG-39) and Gag-R2 (59-
GCTCTGAAATGGCTCTTTTGGCCC-39). The design of the
second round primers involved the incorporation of Roche’s 454
Adaptor sequences and an animal-specific, 4 nucleotide barcode
that allows identification of individual animals in the pooled
sequencing runs. The barcode key can be found in Table S1, and
their position is indicated by a lowercase ‘b’ in the following
primer sequences. Second round primers for tat had sequences
similar to those previously published [15] and were Tat-F3 (59-
GCCTTGCCAGCCCGCTCAGbbbbTGATCCTCGCTTGC-
TAACTG-39) and Tat-R3 (59-GCCTCCCTCGCGCCATCA-
GAGCAAGATGGCGATAAGCAG-39), and the second round
primers for gag were Gag-F3 (59-GCCTTGCCAGCCCGCT-
CAGbbbbCACCATCTAGCGGCAGAGGAGG-39) and Gag-
R3 (59-GCCTCCCTCGCGCCATCAGACCCCAGTTGAAT-
CCATCTCCTG-39). After amplification, each amplicon was
gel purified using the QIAquick gel extraction kit (Qiagen,
Valencia, CA). The amplicons were then quantified on a
NanoDrop (Company), and mixed at equimolar concentrations
within tissues and time points. Massively parallel pyrosequencing
was performed by the University of Pennsylvania, Department
of Genetics Sequencing Facility on a Roche 454 Genome
Sequencer FLX (Branford, CT).
Sequence and statistical analysis
Raw 454 sequencing reads will be available in the NCBI
Sequence Read Archive under accession number SRA027346.1.
Sequences were subjected to several steps of quality control
[41,42]. First, sequences that contained ambiguous nucleotides
and those that did not meet the minimum length requirements (tat:
220 nucleotides; gag: 243 nucleotides) were excluded. Next, each
read was aligned individually to the SIVmac239 wildtype
sequence using ClustalW and barcodes were identified. Reads
where the barcode could not be identified were excluded from the
analysis. Several common insertions and deletions (indels) that
resembled common 454 sequencing artifacts were then identified
and repaired using the wildtype SIVmac239 sequence as a
template. Sequences containing multiple indels and low frequency
sequencing artifacts were excluded. All sequence manipulations
and analyses were performed and implemented in a suite of scripts
written in Python. Statistical analyses were all performed in
GraphPad Prism.
Supporting Information
Figure S1 The distribution of mutated sites in Tat-SL8 differs
between between tissues. The frequency of mutants at each amino
acid position in the tat-SL8 epitope (underlined) and the 5
upstream and downstream positions are shown at day 14 (A) and
day 28 post infection (B) in all four tissues. Animals are grouped by
vaccination (MVADudg-SIV, MVA-SIV, and unvaccinated).
(EPS)
Figure S2 The frequency of Tat-SL8-specific CD8+ Tc e l l s
does not differ between PBMCs, LNs, and RBs at day -28, day
7, and day 14 post infection. The frequency of Tat-SL8-specific
CD8+ T cells in PBMCs, LNs, and RBs is shown for vaccinated
and unvaccinated animals at (A) day -28, (B) day 7, and (C) day
14 post infection. The line represents the average for either
vaccinated (open circle) or unvaccinated (filled square) RMs.
No differences were significantly different (2-way ANOVA,
p.0.05).
(EPS)
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ters. Viral loads are measured in viral RNA copies per mL of
plasma. All immunological parameters were measured via flow
cytometry.
(XLS)
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